-
Mashup Score: 25Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers - 23 day(s) ago
Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these treatments can reduce the effectiveness of ICBs.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments - 1 month(s) ago
Quality of life (QoL) assessment and patient-reported outcomes appear to be crucial in the rationale and interpretation of non-inferiority (NI) trials. The aim of this study was to assess the inclusion of QoL among endpoints in phase III NI oncology trials and the relevance of QoL results in the reporting and interpretation of these studies.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials - 1 month(s) ago
Kaplan-Meier analysis hinges on the assumption that patients who are censored– lost to follow-up, or only recently enrolled on the study– are no different, on average, than patients who are followed. As such, censoring these patients– omitting their future information and taking the average of those who were followed– should not dramatically change the overall estimate. Yet, in a recent clinical trial, two sets of censoring rules– one favored by trialists and one favored by the US Food and Drug Administration– were applied to a progression-free survival (PFS) estimate.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon? - 2 month(s) ago
The phenomenon of stage migration in cancers leads to apparent survival improvement in both lower and higher stages. This is due to an upward migration of patients with adverse biology from lower to higher stages, as well as newcomers in higher stages who are not as clinically advanced as the original cohort in that stage. This epidemiological paradox is called ‘Will Rogers phenomenon’ after the comedian Will Rogers, who, during the large-scale geographic migration of 1930s, had putatively said, ‘When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states’ [1].
Source: www.ejcancer.comCategories: General Medicine News, Partners & KOLsTweet-
In 2014, the diagnostic criteria of Myeloma was modified to include biomarkers (SLiM) in the absence of CRAB, leading to a potential Will Roger's phenomenon. (https://t.co/KysFrX66jt) We hypothesized that a modern cohort of pts with SMM will have a substantially lower risk of… https://t.co/JTx8BBYfhc
-
-
Mashup Score: 26
This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org).
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7A three-arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma - 2 month(s) ago
The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel.
Source: www.ejcancer.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 17
This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org).
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 99Equal Censoring But Still Informative: When The Reasons For Censoring Differ Between Treatment Arms. - 3 month(s) ago
In randomized controlled trials, informative censoring has been described as a potential bias, mainly affecting time-to-event composite endpoints, like progression-free survival (PFS). It is usually suspected in the presence of unequal attrition rates between arms. Early censoring occurs for different reasons: patients may withdraw from a trial because of toxicity, or because of disappointment with their allocation arm. If censoring is more prevalent in one arm because of an excess in toxicity, removing the frailest individuals, a bias is introduced favoring this arm.
Source: www.ejcancer.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 38Sotorasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Multicenter Real-World Experience from the Compassionate Use Program in Germany - 3 month(s) ago
Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the CodeBreaK trials. It remains unclear whether response to sotorasib and outcomes differ in a real-world setting when including patients underrepresented in clinical trials.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma - 5 month(s) ago
Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers - European Journal of Cancer https://t.co/ytcgAH3Coh